Characteristics of the study population
| Genotype | P value | Total (n=100) | |||
| 0RV | 1RV | 2RV | |||
| (n=38) | (n=50) | (n=12) | |||
| Demographics | |||||
| Age (years) | 32.3±10.5 | 32.5±8.8 | 31.9±8.7 | 0.2 | 32.4±9.4 |
| Gender (% female) | 100 | 98 | 100 | 0.4 | 99 |
| Disease duration (years) | 1.9±1.4 | 2.5±2.9 | 2.7±1.7 | 0.3 | 2.3±2.3 |
| Symptom onset to diagnosis (months) | 6.1±13.6 | 11.5±18.4 | 2.7±5.3 | 0.1 | 8.5±15.8 |
| SLE clinical criteria (% positive) | |||||
| Malar rash | 45 | 52 | 33 | 0.5 | 49 |
| Discoid rash | 45 | 36 | 33 | 0.7 | 41 |
| Photosensitivity | 39 | 36 | 67 | 0.2 | 39 |
| Mucosal ulcers | 47 | 48 | 50 | 0.9 | 48 |
| Arthritis | 82 | 68 | 100 | 0.04 | 77 |
| Serositis | 55 | 52 | 41 | 0.7 | 50 |
| Renal | 61 | 49 | 45 | 0.5 | 53 |
| Neurological | 18 | 12 | 0 | 0.2 | 13 |
| Haematological | 50 | 45 | 45 | 0.8 | 50 |
| Immunological | 85 | 71 | 63 | 0.2 | 76 |
| ANA | 97 | 88 | 100 | 0.2 | 93 |
| Serological markers (%) | |||||
| dsDNA | 73 | 65 | 27 | 0.02 | 63 |
| Smith | 64 | 49 | 45 | 0.4 | 54 |
| Ro | 48 | 62 | 36 | 0.2 | 53 |
| La | 13 | 20 | 17 | 0.7 | 15 |
| RNP | 71 | 56 | 82 | 0.2 | 65 |
| Ancillary medications (% taking) | |||||
| Statin | 11 | 0 | 9 | 0.1 | 5 |
| ASA | 0 | 2.1 | 0 | 0.8 | 1 |
| ACE or ARB | 22.2 | 18.8 | 9.0 | 0.1 | 18.9 |
| SLE medications | |||||
| Average prednisolone dose (mg) | 11.5±8.1 | 14.4±11.4 | 10.7±4.5 | 0.3 | 12.8±9.6 |
| Average HCQ dose (mg) | 339±125 | 300±149 | 309±164 | 0.1 | 315 |
| Methotrexate (% taking) | 5.4 | 10.4 | 25 | 0.4 | 10.3 |
| MMF (% taking) | 5.6 | 4.2 | 0.0 | 0.4 | 4.2 |
| AZA (% taking) | 55.6 | 28.6 | 27.3 | 0.2 | 37.3 |
Data presented as number±SD unless indicated as percentages. Serological markers are reported as per cent of patients ever positive for the respective auto-antibodies.
ARB, angiotensin II receptor blockers; ASA, aspirin; AZA, azathioprin; dsDNA, antidouble-stranded DNA antibodies; HCQ, hydroxychloroquine; La, anti-SSB/La (48) antibodies; MMF, mycophenolate mofetil; n, number; RNP, anti-U1RNP antibodies; Ro, anti-SSA/Ro (52 or 60) antibodies; RV, risk variant; Smith, anti-Smith antibodies.